Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: Lilly’s radiopharmaceutical buy; strong third quarter for biotech financing; Novartis’s nephropathy results; US ICER runs cost analysis on first batch of drugs; and the outlook for US FTC oversight of biopharma M&A.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 6 October 2023, including: Eli Lilly and Company’s radiopharmaceutical buy; strong third quarter for biotech financing; Novartis AG’s nephropathy results; US ICER runs cost analysis on first batch of drugs; and the outlook for US FTC oversight of biopharma M&A.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Lilly Looks To Take POINT On Emerging Cancer Radiopharmaceutical Space" - Scrip, 3 Oct, 2023.)
(Also see "Biotech IPOs Get Bigger, But Not Necessarily Better" - Scrip, 4 Oct, 2023.)
(Also see "Muted APPLAUSE For Novartis In IgAN" - Scrip, 2 Oct, 2023.)
(Also see "ICER Hands CMS A Drug Price Negotiation Cheat Sheet" - Scrip, 2 Oct, 2023.)
(Also see "Podcast: How Will Greater FTC Scrutiny Affect Biopharma M&A Activity?" - Scrip, 3 Oct, 2023.)